

Flow-chart for HCV therapy in HIV-infected patients (v18; 03/16)

SHCS-ID:	HCV-Genotype:.....	HCV Treatment history <input type="checkbox"/> Treatment naive <input type="checkbox"/> Treatment experienced : - IFN based regimen <input type="checkbox"/> - First generation PI <input type="checkbox"/> - DAA <input type="checkbox"/> if yes: <input type="checkbox"/> SOF <input type="checkbox"/> LDV <input type="checkbox"/> DCV <input type="checkbox"/> SIM <input type="checkbox"/> 3D <input type="checkbox"/> GZR/EBR	*Reasons for stopping HCV therapy: 1. HCV virological failure/stopping rule 2. Anemia 3. Leukopenia 4. Thrombocytopenia 5. Depression 6. Rash 7. Other side effects, please specify:	Reasons for starting HCV therapy: <input type="checkbox"/> Fibrosis: - Stage: <input type="checkbox"/> Extrahepatic manifestation: - Type:.....
	Fibrosis assessm.: Date: Biopsy Metavir: Date: Fibroscan:..... kPa	Cirrhosis <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> unknown Child-Pugh-score:	RAVs <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> not tested If Yes which one:.....	

Date of Tx start:	<i>Start or change of dosage = dose. Stop=↘; unchanged = →. Indicate treatment interruption of ≥ 1 day. For a stop always indicate predominant reason for each drug, see legend).</i>														
	Date and treatment week (for university centers: mandatory visits with sample storage at weeks 0,2,4, at end of treatment and at treatment failure)														
	Baseline														
HCV DAA #1 (indicate product name) (mg/d)															
HCV DAA #2 (indicate product name)(mg/d)															
HCV DAA #3 (indicate product name)(mg/d)															
Ribavirin (indicate product name)(mg/d)															
Interferon-alpha (indicate product name)(µg/w)															
Reason for stopping drug (see legend*)															
Other adverse event															
HCV RNA (log ₁₀ IU/ml), differentiate between <15 IU/ml and not detected															
Adherence: How often did you miss a dose of your HCV medication?	Every day	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	More than 1/week	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Less than 1/week	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Never	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

For university centers: Weeks 0, 2, 4, end of treatment and at treatment failure: Measure HCV RNA and store 2 plasma aliquots (SHCS #688)	HCV Treatment outcome <input type="checkbox"/> SVR: Undetectable HCV RNA ≥12 weeks after end of treatment <input type="checkbox"/> Relapse: Undetectable HCV RNA at end of therapy, detectable ≥12 after end of treatment <input type="checkbox"/> Breakthrough: Reappearance of HCV RNA at any time during treatment after virological response <input type="checkbox"/> Virological non response <input type="checkbox"/> Premature discontinuation of Tx: Insufficient duration or dosage of previous therapy due to side effects <input type="checkbox"/> Other:	Notes: After treatment outcome: Send copy of CRF to charles.bequelin@insel.ch or FAX: 0316328246
--	---	--